Stem Cell Therapy for Alzheimer's Disease

What This Article Covers

Stem cell therapy for Alzheimer's disease is an active area of clinical research, not an available treatment. Early-phase trials using mesenchymal stem cells (MSCs) have shown these infusions can be given safely and have produced some encouraging signals — including a well-publicized Phase 2a trial that hinted at slowed brain-volume loss — but no stem cell product has demonstrated proven clinical benefit, and none is FDA-approved for Alzheimer's. This article summarizes the real trial data and who might reasonably consider enrolling in a study.

Overview

Alzheimer's involves progressive loss of neurons and synapses, chronic neuroinflammation, and buildup of amyloid and tau proteins. Approved drugs like lecanemab and donanemab target amyloid clearance. Stem cell research takes a different approach: rather than replacing lost neurons, most investigational cell therapies aim to modulate the brain's inflammatory and support environment — a much earlier-stage strategy.

How It's Thought to Work

Mesenchymal stem cells (MSCs) — typically sourced from bone marrow, umbilical cord tissue, or fat — aren't being studied as replacement neurons. Once infused, they're thought to act mainly through paracrine signaling: releasing anti-inflammatory cytokines, growth factors, and exosomes that may calm neuroinflammation, support the brain's vascular environment, and potentially influence clearance of amyloid and tau. This is a “support and modulate” hypothesis, not a “regenerate lost brain tissue” one.

What the Evidence Shows

The most advanced program is Longeveron's Lomecel-B (laromestrocel), an allogeneic bone-marrow-derived MSC product. Its Phase 2a CLEAR MIND trial enrolled 49 people with mild Alzheimer's across 10 U.S. sites, randomized to a single infusion, repeated infusions, or placebo. Results published in Nature Medicine in 2025 reported that the trial met its primary safety endpoint — no new safety concerns, no hypersensitivity reactions, and no amyloid-related imaging abnormalities (ARIA), a side effect that has limited some approved anti-amyloid drugs. On secondary measures, the single-dose group showed statistically significant slowing of left hippocampal volume loss versus placebo, with pooled groups showing some preservation of brain volume and daily-living scores. These are genuinely encouraging signals — but they come from a small, short trial built to test safety, not powered to prove cognitive benefit. Longeveron has since agreed with the FDA on a single, pivotal Phase 2/3 trial with a potential accelerated pathway; as of an August 2026 update, that trial hasn't started (targeted for late 2026, funding-dependent). The furthest-along program hasn't yet run the study that would prove whether it works.

Other research is more mixed. A Korean Phase IIa trial (Dementia and Neurocognitive Disorders, 2025) tested MSCs injected into the brain's ventricles, with and without adjuvant dexamethasone, and found no significant clinical benefit — though it reported reductions in CSF biomarkers (amyloid-beta, tau) alongside more treatment-related adverse events (fever, headache, nausea) than placebo. Separately, a small FDA-cleared Phase 1 trial of autologous, fat-derived MSCs (Hoag Memorial Presbyterian Hospital) reported no serious adverse events and preliminary signals of reduced tau/amyloid and improved cognitive scores in a handful of patients; a larger 115-participant Phase 2 has since been cleared. Overall: safety signals have held up across MSC sources and routes, one program shows promising imaging/biomarker hints, and at least one well-conducted trial found no measurable benefit. No trial has yet been large or long enough to show stem cell therapy meaningfully slows Alzheimer's progression.

Who Might Be a Candidate (for a Clinical Trial)

Because no stem cell therapy is approved for Alzheimer's, the relevant question isn't “am I a candidate for treatment” but “am I a candidate for a clinical trial.” People who might discuss enrollment with their neurologist include those who:

• Have a confirmed diagnosis of mild Alzheimer's (most trials so far have enrolled early-stage patients)
• Want to contribute to research on cell-based, anti-inflammatory approaches
• Meet the criteria of an actively enrolling, registered trial (searchable at ClinicalTrials.gov)
• Accept that any benefit is unproven and participation is a research contribution, not a treatment

Unregulated clinics offering “stem cell infusions” for Alzheimer's outside a registered trial are not supported by the evidence above and are not FDA-approved.

Bottom Line

Stem cell therapy for Alzheimer's disease is a legitimate, active research direction — not an available treatment. The best data so far, from Longeveron's Phase 2a trial, are encouraging on safety and hint at slowed brain-volume loss, but come from a small trial not designed to prove cognitive benefit, while a separate, well-run trial found no clinical benefit at all. No stem cell product is FDA-approved for Alzheimer's, and even the most advanced program hasn't started the pivotal trial that would test whether it truly works. Treat this strictly as a clinical-trial option today, and view any clinic marketing stem cell “treatment” for Alzheimer's outside a registered trial with real skepticism.